Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130106 | 0.88 | ALDH1A1 (0.36) | TDP1ALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL1726191 | 0.87 | TDP1 (0.37) | TDP1ALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL2129981 | 0.86 | SLC6A5 (0.38) | TDP1ALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL2601748 | 0.85 | TDP1 (0.44) | RAD52UHRF1TDP1SMARCA2ALDH1A1 | |
| SCHEMBL2601754 | 0.82 | ALDH1A1 (0.45) | TDP1ALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL2601755 | 0.82 | ALDH1A1 (0.45) | ALDH1A1LMNAHTTNPSR1KMT2A | |
| SCHEMBL2601756 | 0.81 | ALDH1A1 (0.44) | TDP1ALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL2605586 | 0.80 | ALDH1A1 (0.44) | TDP1ALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL14237587 | 0.76 | TDP1 (0.36) | TDP1ALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL14237643 | 0.76 | TDP1 (0.37) | TDP1ALDH1A1LMNAHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179789-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-12-14 | — | — | US | disclosed |
| US-9562051-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562051-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-07 | — | — | US | disclosed |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-04-26 | — | — | US | disclosed |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-04-26 | — | — | US | disclosed |
| US-7858627-B2 | Topoisomerase-targeting agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010102219-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20090258890-A1 | TOPOISOMERASE-TARGETING AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-10-15 | — | — | US | disclosed |
| US-7517867-B2 | Topoisomerase-targeting agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070225289-A1 | Topoisomerase-targeting agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225289-A1 | Topoisomerase-targeting agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-09-27 | — | — | US | disclosed |
| US-7208492-B2 | Topoisomerase-targeting agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208492-B2 | Topoisomerase-targeting agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179789-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | TOP2B, TOP1, TOP2A | RAD52 630/4885UHRF1 999/4885TDP1 18/4885 |
| US-20070225289-A1 | Topoisomerase-targeting agents | TOP1, TOP2A, TOP2B | RAD52 142/4885UHRF1 1305/4885TDP1 8/4885 |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | TOP2B, TOP1, TOP2A | RAD52 630/4885UHRF1 999/4885TDP1 18/4885 |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | TOP2B, TOP1, TOP2A | RAD52 630/4885UHRF1 999/4885TDP1 18/4885 |
| US-20090258890-A1 | TOPOISOMERASE-TARGETING AGENTS | TOP1, TOP2A, TOP2B | RAD52 129/4885UHRF1 1402/4885TDP1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.